mRNA / LNP CDMOs — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform

mRNA / LNP manufacturers on CDMO Signal: 40 listed. 7 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Pfizer CentreOne (also makes its own products, Signal Score 90.1), BioNTech (Mfg Services) (also makes its own products, Signal Score 82.1) and Merck KGaA / MilliporeSigma (CDMO) (also makes its own products, Signal Score 81.9). Outside that set, higher Signal Scores on this list include FUJIFILM Diosynth Biotechnologies (Signal Score 86.7), Corden Pharma (Signal Score 83.1) and ReciBioPharm (Signal Score 82.9). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

mRNA/LNP CDMOs with the most regulatory evidence on file

Catalent
76.1
Tampa, FL
24 FDA inspections · 39 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-22 · VAI
Warning letter 2025-11-20
See the evidence →
FUJIFILM Diosynth Biotechnologies
86.7
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
0 FDA inspections · 35 EMA/MHRA GMP certs
Last FDA inspection: None on file
See the evidence →
Corden Pharma
83.1
Plankstadt, DE · Caponago, IT · Boulder, CO
5 FDA inspections · 17 EMA/MHRA GMP certs
Last FDA inspection: 2025-11-14 · NAI
See the evidence →
Curia (RNA/Advanced)
79.5
Albany, NY · Albuquerque, NM
2 FDA inspections · 18 EMA/MHRA GMP certs
Last FDA inspection: 2025-12-02 · NAI
See the evidence →
Lonza
72.8
Basel, Switzerland
11 FDA inspections · 8 EMA/MHRA GMP certs
Last FDA inspection: 2025-09-29 · VAI
See the evidence →
40
CDMOs tracked
32
Fully scored
17
With FDA records
67
FDA inspections
179
EMA/MHRA GMP certs
2
Warning letters

mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.

Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 21 NAI (no action), 44 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (50), Germany (42), Denmark (29), UNITED KINGDOM (22), Italy (21).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PC
Kalamazoo, MI · McPherson, KS
Fully evidenced
Also makes its own products
90.1 100.0 4 insp · 14 GMP 2025-12-16 · NAI — 366 programs
2
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
3
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
83.1 99.3 5 insp · 17 GMP 2025-11-14 · NAI — —
4
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
5
WK
Jena, DE · Amsterdam, NL · San Diego, CA
82.9 100.0 1 insp · 13 GMP 2023-12-07 · VAI — —
6
BNT
Mainz, DE · Marburg, DE
Fully evidenced
Also makes its own products
82.1 100.0 0 insp · 8 GMP None on file — 28 programs
7
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
81.9 98.8 2 insp · 2 GMP 2025-04-28 · VAI — 22 programs
8
KE
Seraing, BE
81.6 99.9 1 insp · 4 GMP 2024-02-26 · VAI — —
9
EK
Birmingham, AL · Vancouver, BC
81.5 99.8 2 insp · 2 GMP 2025-09-11 · NAI — —
10
ND
Milford, MA
80.3 100.0 4 insp · 0 GMP 2026-08-12 · NAI — —
11
AE
Fargo, ND
Hiring · 35 open roles
80.3 100.0 1 insp · 0 GMP 2024-11-08 · NAI — —
12
CRA
Albany, NY · Albuquerque, NM
Hiring · 48 open roles
79.5 100.0 2 insp · 18 GMP 2025-12-02 · NAI — —
13
UM
Boston, MA
78.7 96.7 2 insp · 0 GMP 2025-12-18 · VAI — —
14
MR
Norwood, MA
Fully evidenced
In-house manufacturer
77.9 100.0 4 insp · 4 GMP 2025-11-21 · NAI — 10 programs
15
Tampa, FL
Hiring · 311 open roles
76.1 77.3 24 insp · 39 GMP 2026-05-22 · VAI
Warning letter 2025-11-20
— —
16
CVC
Tubingen, DE
Fully evidenced
Also makes its own products
75.3 100.0 0 insp · 7 GMP None on file — 4 programs
17
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
18
DH
Washington, DC
Platform provider
73.0 — — None on file — —
19
Basel, Switzerland
Hiring · 100+ open roles
Fully evidenced
72.8 86.6 11 insp · 8 GMP 2025-09-29 · VAI — 1 program
20
CG
Marlborough, MA · Uppsala, SE
Platform provider
65.5 — — None on file — —
21
PBI
Pennington, NJ · Nanjing, CN
64.0 — — None on file — —
22
TL
San Diego, CA
Reagent supplier
63.0 — — None on file — —
23
HP
63.0 — — None on file — —
24
SB
Incheon, South Korea, Rockville, Maryland, USA
Hiring · 12 open roles
61.5 — — None on file Available —
25
PN
Vancouver, BC, Canada
Reagent supplier
60.5 — — None on file — —
26
AT
San Diego, CA
Also makes its own products
60.5 — — None on file — —
27
CC
Toronto, ON, Canada
Academic / national centre
59.0 — — None on file — —
28
RR
Guangzhou, China
59.0 — — None on file — —
29
SP
Seoul, South Korea
59.0 — — None on file — —
30
AC
Vancouver, BC
Reagent supplier
56.5 — — None on file — —
31
QB
Gosselies, BE
Platform provider
56.5 — — None on file — —
32
EH
Planegg, DE
Also makes its own products
56.5 — — None on file — —
—
Frankfurt am Main, Germany
Profiled — 1 insp · 0 GMP 2022-11-15 · VAI — —
— Profiled — 0 insp · 5 GMP None on file — —
—
Takasago, Hyogo, Japan
Also makes its own products
Profiled — 1 insp · 0 GMP 2025-11-14 · VAI — —
—
Alabaster, Alabama, United States
Also makes its own products
Profiled — 1 insp · 0 GMP 2023-07-07 · VAI — —
—
Seoul, South Korea
Also makes its own products
Profiled — — None on file — —
—
Knoxville, Tennessee, USA
Profiled — — None on file — —
—
Bloomington, Indiana, USA
Profiled — — None on file — —
—
North Brunswick, New Jersey, USA
Profiled — — None on file — —
How we score CDMOs →

What to evaluate in a mRNA / LNP CDMO

IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.

IVT mRNA synthesis — how do CDMOs differ on scale and capping?

IVT (in vitro transcription) is the upstream step of mRNA manufacturing, using linearized plasmid DNA or PCR products as template. CDMOs differ meaningfully on IVT batch scale (from milligrams for early clinical to multi-gram commercial), capping strategy (co-transcriptional using CleanCap or trinucleotide analogs vs enzymatic post-transcription with vaccinia D1), and template strategy (linearized plasmid is standard; PCR is faster for early work but harder to scale). Sponsors should confirm which platform the CDMO validates and how yields hold at target scale — capping efficiency directly impacts translation and immunogenicity, and cannot be corrected downstream.

LNP formulation — microfluidics, particle size, and lipid sourcing

Lipid nanoparticle (LNP) formulation is the differentiator most CDMOs are still building against. Microfluidic mixing (T-mixer or NanoAssemblr platforms) determines particle-size control, encapsulation efficiency, and reproducibility across scale-up. Ionizable-lipid supply is a real constraint — most novel LNP formulations depend on lipids from a narrow set of suppliers (Croda, Merck, Cayman) or in-house-synthesized proprietary lipids. Sponsors should ask about freedom-to-operate on the CDMO's LNP platform, GMP lipid sourcing plans, and demonstrated PDI (polydispersity index) control across process transfers.

Plasmid template supply — in-house vs sourced?

mRNA manufacturing needs GMP-grade plasmid DNA as the transcription template. CDMOs that offer both plasmid production and mRNA/LNP under one roof cut a supply seam and simplify comparability. The Plasmid DNA CDMO ranking covers the specialized plasmid manufacturers; CDMOs appearing in both mRNA and plasmid rankings offer integrated capability. For programs where plasmid is sourced externally, verify comparability data between the plasmid supplier's lots and the CDMO's validated IVT process — plasmid-to-mRNA yield is highly sensitive to plasmid quality.

How CDMO Signal computes the mRNA / LNP ranking

The mRNA / LNP Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications (NAI, VAI, OAI), Warning Letter history, and EMA/MHRA GMP certificate density. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint. Financial Stability (20%) draws on public/private status and parent-company backing — mRNA/LNP is capital-intensive and the platform is still consolidating post-COVID, so parent-company health is a real reliability signal. Capacity Intelligence (20%) counts the manufacturing sites and modalities listed on the profile; job postings are not a score input. Press announcements and SEC filings are shown on profiles as company signals and do not change any score. Full weightings at cdmosignal.com/methodology.

mRNA / LNP CDMOs — Frequently Asked Questions

Who are the top mRNA / LNP CDMOs?
Among mRNA / LNP manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Pfizer CentreOne, BioNTech (Mfg Services), Merck KGaA / MilliporeSigma (CDMO). The table above is the full list. CDMOs cannot pay to change a score.
How many mRNA / LNP CDMOs have FDA inspection records?
CDMO Signal tracks 17 mRNA / LNP CDMOs with FDA inspection records and 179 EMA/MHRA GMP certificates across the group.
What should I look for in an mRNA / LNP CDMO?
Look for proven IVT mRNA synthesis at your scale, LNP formulation via microfluidics, a clear template/plasmid supply strategy, cold-chain capability, and a clean FDA and EMA/MHRA record.
Do mRNA CDMOs also make the LNP and plasmid?
Capabilities vary. Some CDMOs offer end-to-end IVT mRNA, LNP formulation, and GMP plasmid; others specialize in one step and coordinate partners. Check each profile's modality coverage above.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this mRNA/LNP shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Plasmid DNA CDMOs Lentiviral Vector CDMOs AAV / Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector